10 years of SAGER sees progress, but not parity The Lancet Rheumatology ++... ++

10 years of SAGER sees progress, but not parity The Lancet Rheumatology https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00185-2/fulltext?dgcid=raven_jbs_etoc_email Jul 2026 Volume 8Number 7e493-e586 https://www.thelancet.com/journals/lanrhe/issue/vol8no7/PIIS2665-9913(26)X2006-9 Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial Prof Eric F Morand, PhDa Send email to eric.morand@monash.edu ∙ Prof Victoria P Werth, MDb ∙ Prof Joerg Wenzel, MD Prof Joerg Wenzel, MD Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00337-6/abstract?dgcid=raven_jbs_etoc_feature_lanrhe Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial Wing-Yi Wong, MDa,† ∙ Dewi Rijnenberg, MDa,† ∙ Valentin M D Baloche, PhDa ∙ Sofie L M Blokland, PhDa ∙ Paco M J Welsing, PhDa ∙ Femke Bonte-Mineur, MDc ∙ et al. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00075-5/abstract?dgcid=raven_jbs_etoc_feature_lanrhe